Coronary artery disease in Africa and the Middle East

Therapeutics and Clinical Risk Management

Volumn 8, Issue , 2012, Pages 65-72

  Almahmeed, Wael ^a   Samir Arnaout, Mohamad ^b   Chettaoui, Rafik ^c   Ibrahim, Mohsen ^d   Ibrahim Kurdi, Mohamed ^e   Awad Taher, Mohamed ^f   Mancia, Giuseppe ^g  

^a SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c General and Cardiovascular Clinic of Tunis   (Tunisia)

^d CAIRO UNIVERSITY   (Egypt)

^e KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^f AIN SHAMS UNIVERSITY   (Egypt)

^g UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Beta blockers; Cardiovascular disease; Cardiovascular risk factors; Coronary heart disease; Heart failure

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; HEPARIN; NITRATE;

AFRICA; ALGERIA; CALORIC INTAKE; CARDIAC IMAGING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CULTURAL FACTOR; DIABETES MELLITUS; DYSLIPIDEMIA; EGYPT; ENVIRONMENTAL FACTOR; GEOGRAPHY; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HYPERTENSION; ISCHEMIC HEART DISEASE; LEBANON; MIDDLE EAST; MOROCCO; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PHYSICAL ACTIVITY; PREVALENCE; REVIEW; RISK REDUCTION; SAUDI ARABIA; SEDENTARY LIFESTYLE; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TUNISIA; UNITED ARAB EMIRATES; UNSTABLE ANGINA PECTORIS;

EID: 84875290902     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S26414     Document Type: Review

References (61)

1. World Health Organization. Data and statistics: mortality and health status. Available from: http://www.who.int/research/en/. Accessed January 12, 2012.
2. Okrainec K, Banerjee DK, Eisenberg MJ. Coronary artery disease in the developing world. Am Heart J. 2004;148:7-15.
3. The Task Force on Beta-Blockers of the European Society of Cardiology. Expert consensus document on b-adrenergic receptor blockers. Eur Heart J. 2004;25:1341-1362.
4. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Eur Heart J. 2007;28:1462-1536.
5. National Institute for Health and Clinical Excellence. NICE clinical guideline 127. Hypertension: clinical management of primary hypertension in adults. Available from: http://www.nice.org.uk/nicemedia/live/13561/56008/56008.pdf. Accessed January 12, 2012.
6. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364: 937-952.
7. Al Suwaidi J, Zubaid M, El-Menyar AA, et al. Prevalence and outcome of cigarette and waterpipe smoking among patients with acute coronary syndrome in six Middle-Eastern countries. Eur J Cardiovasc Prev Rehabil. February 25, 2011. [Epub ahead of print.]
8. Guindon DE, Boisclair G. World Health Organization Tobacco Free Initiative. Past, Current and Future Trends in Tobacco use. HNP discussion paper series; economics of tobacco control paper no. 6 (2003). Available from: http://siteresources.worldbank.org/HEALTHNUTRITIONANDPOPULATION/Resources/281627-1095698140167/Guindon-PastCurrent-whole.pdf. Accessed January 12, 2012.
9. Ali WM, Zubaid M, Al-Motarreb A, et al. Association of khat chewing with increased risk of stroke and death in patients presenting with acute coronary syndrome. Mayo Clin Proc. 2010;85:974-980.
10. Sharraf YA, Bedir RA, Ibrahim MM. Prevalence and correlates of hypertensive complications in Egyptians. Med J Cairo Univ. 2003; 71:747-753.
11. Ibrahim MM, Rizk H, Appel LJ, et al. Hypertension prevalence, awareness, treatment, and control in Egypt. Results from the Egyptian National Hypertension Project (NHP). NHP Investigative Team. Hypertension. 1995;26:886-890.
12. Ibrahim MM, Appel LJ, Rizk HH, et al. Cardiovascular risk factors in normotensive and hypertensive Egyptians. J Hypertens. 2001;19: 1933-1940.
13. Abchee A, Puzantian H, Azar ST, et al. Predictors of coronary artery disease in the Lebanese population. Thromb Res. 2006;117: 631-637.
14. Sibai AM, Tohme RA, Saade GA; for Lebanese Interventional Coronary Registry (LICOR) Working Group. Coronary angiography in Lebanon: use and overuse. Int J Cardiol. 2008;125:422-424.
15. Sibai AM, Tohme RA, Saade GA, et al. The appropriateness of use of coronary angiography in Lebanon: implications for health policy. Health Policy Plan. 2008;23:210-217.
16. Dakik HA, Abdallah M, Karrowni W, et al. International variations in the ischemic burden post-acute myocardial infarction: prognostic implications. J Nucl Cardiol. 2009;16:251-254.
17. Al-Nozha MM, Abdullah M, Arafah MR, et al. Hypertension in Saudi Arabia. Saudi Med J. 2007;28:77-84.
18. Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, et al. Diabetes mellitus in Saudi Arabia. Saudi Med J. 2004;25:1603-1610.
19. Al-Nozha MM, Arafah MR, Al-Mazrou YY, et al. Coronary artery disease in Saudi Arabia. Saudi Med J. 2004;25:1165-1171.
20. Newson-Smith MS. Importing health conditions of expatriate workers into the United Arab Emirates. Asia Pac J Public Health. 2010;22: 25S-30S.
21. Awad HH, Zubaid M, Alsheikh-Ali AA, et al. Comparison of characteristics, management practices, and outcomes of patients between the Global Registry and the Gulf Registry of Acute Coronary Events. Am J Cardiol. 2011;108:1252-1258.
22. Al-Jarallah M, Al-Mallah MH, Zubaid M, et al. Trends in the use of evidence-based therapies early in the course of acute myocardial infarction and its influence on short term patient outcomes. Open Cardiovasc Med J. 2011;5:171-178.
23. Steg PG, Goldberg RJ, Gore JM, et al; GRACE Investigators. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol. 2002;90: 358-363.
24. Omran AR. The epidemiological transition: a theory of the epidemiology of population change. Millbank Mem Fund Q. 1971;75:509-538.
25. Ghannem H. The challenge of preventing cardiovascular disease in Tunisia. Prev Chronic Dis. 2006;3:A13.
26. Ben Romdhane H, Haouala H, Belhani A, et al. Epidemiological transition and health impact of cardiovascular disease in Tunisia. Tunis Med. 2005;83 Suppl 5:1-7.
27. National Institute for Statistics. Available from: http://www.ins.nat.tn. Accessed September 8, 2011.
28. Ghannem H, Hadj Fredj A. Prevalence of cardiovascular risk factors in the urban population of Soussa in Tunisia. J Public Health Med. 1997; 19:392-396.
29. Tazi MA, Abir-Khalil S, Chaouki N, et al. Prevalence of the main cardiovascular risk factors in Morocco: results of a National Survey, 2000. J Hypertens. 2003;21:897-903.
30. TAHINA Project website. Available from: http://www.ins.nat.tn. Accessed January 12, 2012.
31. Albert MA. Heart failure in the urban African enclave of Soweto: a case study of contemporary epidemiological transition in the developing world. Circulation. 2008;118:2323-2325.
32. Stewart S, Wilkinson D, Hansen C, et al. Predominance of heart failure in the Heart of Soweto Study cohort: emerging challenges for urban African communities. Circulation. 2008;118:2360-2367.
33. Tibazarwa K, Ntyintyane L, Sliwa K, et al. A time bomb of cardiovascular risk factors in South Africa: results from the Heart of Soweto Study "Heart Awareness Days". Int J Cardiol. 2009;132: 233-239.
34. Kengne AP, Ntyintyane LM, Mayosi BM. A systematic overview of prospective cohort studies of cardiovascular disease in sub-Saharan Africa. Cardiovasc J Afr. 2011;22:1-10.
35. Ntandou G, Delisle H, Agueh V, Fayomi B. Abdominal obesity explains the positive rural-urban gradient in the prevalence of the metabolic syndrome in Benin, West Africa. Nutr Res. 2009;29:180-189.
36. Salman Z, Kirk GD, Deboer MD. High rate of obesity-associated hypertension among primary schoolchildren in Sudan. Int J Hypertens. 2010;2011:629492.
37. Fourth Joint Task Force of the European Society of Cardiology and other Societies on cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur J Cardiovasc Prev Rehabil. 2007; 14 Suppl 2:E1-E40.
38. Al-Sarraj T, Saadi H, Volek JS, Fernandez ML. Metabolic syndrome prevalence, dietary intake, and cardiovascular risk profile among overweight and obese adults 18-50 years old from the United Arab Emirates. Metab Syndr Relat Disord. 2010;8:39-46.
39. Al-Rethaiaa AS, Fahmy AE, Al-Shwaiyat NM. Obesity and eating habits among college students in Saudi Arabia: a cross sectional study. Nutr J. 2010;9:39.
40. Galal OM. The nutrition transition in Egypt: obesity, undernutrition and the food consumption context. Public Health Nutr. 2002;5: 141-148.
41. Baron-Epel O, Haviv A, Garty N, Tamir D, Green MS. Who are the sedentary people in Israel? A public health indicator. Isr Med Assoc J. 2005;7:694-699.
42. Bryan SN, Tremblay MS, Pérez CE, Ardern CI, Katzmarzyk PT. Physical activity and ethnicity: evidence from the Canadian Community Health Survey. Can J Public Health. 2006;97:271-276.
43. Glans F, Eriksson KF, Segerström A, Thorsson O, Wollmer P, Groop L. Evaluation of the effects of exercise on insulin sensitivity in Arabian and Swedish women with type 2 diabetes. Diabetes Res Clin Pract. 2009;85:69-74.
44. AlQuaiz AM, Tayel SA. Barriers to a healthy lifestyle among patients attending primary care clinics at a university hospital in Riyadh. Ann Saudi Med. 2009;29:30-35.
45. Sawaya JI, Jazra C, Farhat F, Alam S, Eid EV, Sabra R. In-hospital mortality after acute myocardial infarction in Lebanon: incidence, associations, and influence of newer treatment regimens. J Med Liban. 2000;48:63-69.French.
46. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008;29:2388-2442.
47. Mendis S, Abegunde D, Yusuf S, et al. WHO study on prevention of recurrences of myocardial infarction and stroke (WHO-PREMISE). Bulletin of the World Health Organization 2005;83:820-828.Available from: http://www.who.int/bulletin/volumes/83/11/820.pdf. Accessed January 12, 2012.
48. Alsheikh-Ali AA, Al-Mahmeed W, Porath A, et al. Prevalence and treatment of cardiovascular risk factors in outpatients with atherothrombosis in the Middle East. Heart Asia. 2011:77e81.
49. Abdallah MH, Arnaout S, Karrowni W, Dakik HA. The management of acute myocardial infarction in developing countries. Int J Cardiol. 2006;111:189-194.
50. Zubaid M, Rashed WA, Al-Khaja N, et al. Clinical presentation and outcomes of acute coronary syndromes in the gulf registry of acute coronary events (Gulf RACE). Saudi Med J. 2008;29:251-255.
51. El-Menyar A, Zubaid M, Rashed W, et al. Comparison of men and women with acute coronary syndrome in six Middle Eastern countries. Am J Cardiol. 2009;104:1018-1022.
52. Alhabib KF, Hersi A, Alsheikh-Ali AA, et al. Prevalence, predictors, and outcomes of conservative medical management in non-ST-segment elevation acute coronary syndromes in Gulf RACE-2. Angiology. 2011; May 11. [Epub ahead of print.]
53. Alhabib K, Hersi A, Almahmeed W, et al. Baseline characteristics, management practices, and long-term outcomes of Middle Eastern patients in the Second Gulf Registry of Acute Coronary Events (Gulf RACE-2). Ann Saudi Med. 2012;32:9-18.
54. Zubaid M, Rashed WA, Almahmeed W, et al. Management and outcomes of Middle Eastern patients admitted with acute coronary syndromes in the Gulf Registry of Acute Coronary Events (Gulf RACE). Acta Cardiol. 2009;64:439-446.
55. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201-207.
56. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressurelowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410-1419.
57. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006;174: 1737-1742.
58. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
59. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895-906.
60. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
61. Silvestri A, Galetta P, Cerquetani E, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J. 2003;24: 1928-1932.